HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Oxidation of raloxifene to quinoids: potential toxic pathways via a diquinone methide and o-quinones.

Abstract
Raloxifene was approved in 1997 by the FDA for the treatment of osteoporosis in postmenopausal women, and it is currently in clinical trials for the chemoprevention of breast cancer. Before widespread use as a chemopreventive agent in healthy women, the potential cytotoxic mechanisms of raloxifene should be investigated. In the current study, raloxifene was incubated with GSH and either rat or human liver microsomes, and the metabolites and GSH conjugates were characterized using liquid chromatography-tandem mass spectrometry. Raloxifene was converted to raloxifene diquinone methide GSH conjugates, raloxifene o-quinone GSH conjugates, and raloxifene catechols. For comparison, three raloxifene catechols were synthesized and characterized. In particular, 7-hydroxyraloxifene was found to oxidize to the 6,7-o-quinone. As compared with raloxifene diquinone methide, which has a half-life of less than 1 s in phosphate buffer, the half-life of raloxifene 6,7-o-quinone was much longer at t(1/2) = 69 +/- 2.5 min. The stability offered by raloxifene 6,7-o-quinone implies that it may be more toxic than raloxifene diquinone methide. Cytotoxicity studies in the human breast cancer cell lines S30 and MDA-MB-231 showed that 7-hydroxyraloxifene was more toxic than raloxifene in both cell lines. These results suggest that raloxifene could be metabolized to electrophilic and redox active quinoids, which have the potential to cause toxicity in vivo.
AuthorsLinning Yu, Hong Liu, Wenkui Li, Fagen Zhang, Connie Luckie, Richard B van Breemen, Gregory R J Thatcher, Judy L Bolton
JournalChemical research in toxicology (Chem Res Toxicol) Vol. 17 Issue 7 Pg. 879-88 (Jul 2004) ISSN: 0893-228X [Print] United States
PMID15257612 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Benzoquinones
  • Indolequinones
  • Selective Estrogen Receptor Modulators
  • quinone methide
  • quinone
  • Raloxifene Hydrochloride
  • Glutathione
Topics
  • Animals
  • Benzoquinones (metabolism, toxicity)
  • Breast Neoplasms (drug therapy, pathology)
  • Cell Line, Tumor
  • Cell Survival (drug effects)
  • Female
  • Glutathione (analogs & derivatives, metabolism)
  • Humans
  • Indolequinones (analysis, metabolism)
  • Microsomes, Liver (drug effects, metabolism)
  • Oxidation-Reduction
  • Raloxifene Hydrochloride (analogs & derivatives, metabolism, toxicity)
  • Rats
  • Rats, Sprague-Dawley
  • Selective Estrogen Receptor Modulators (metabolism, toxicity)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: